Overall, our observations suggest that adiponectin might be a valuable tool in NAFL vs. NASH stratification; however, its role as a biomarker in NAFLD can be challenged by risk-conferring genetic variants, such as the PNPLA3 c.444G allele, and can benefit from combination panels, such as the one presented comprising serum lipids. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.